文献速递白血病

Trib1通过调控Hoxa9的转录程序促进急性髓系白血病进展

Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9.
PubMed 文献 · Blood · 2021-01-01

研究揭示假激酶Trib1通过降解C/EBPα p42并轻度依赖MEK/ERK通路,增强Erg、Spns2、Rgl1和Pik3cd位点超级增强子的H3K27Ac信号及mRNA表达,从而调控Hoxa9相关转录程序;沉默Erg可消除Trib1过表达带来的生长优势,BRD4抑制剂JQ1在体内外以Trib1/Erg依赖方式抑制AML细胞生长,人AML细胞系中亦观察到TRIB1上调ERG,提示Trib1是Hoxa9相关AML的潜在治疗靶点。

要点

  • Trib1通过降解C/EBPα p42并轻度依赖MEK/ERK通路,增强Erg等基因超级增强子活性。
  • Erg是Trib1/Hoxa9轴的关键下游靶点,沉默Erg可消除Trib1过表达的生长优势。
  • BRD4抑制剂JQ1在体内外以Trib1/Erg依赖方式抑制AML细胞生长。

核心结论

  • Trib1通过调控Hoxa9相关超级增强子和转录程序促进急性髓系白血病进展,是Hoxa9相关AML的潜在治疗靶点。

研究设计与样本

  • 基础研究,采用染色质免疫沉淀测序、基因沉默及体内外药物处理等方法,探讨Trib1调控Hoxa9转录活性的机制。

主要发现

  • 染色质免疫沉淀测序分析发现Erg、Spns2、Rgl1和Pik3cd位点超级增强子的组蛋白H3K27Ac信号增加,这些基因的信使RNA表达也增加。
  • 超级增强子活性的改变主要通过Trib1降解C/EBPα p42实现,MEK/ERK通路有少量贡献。
  • 沉默Erg可消除Trib1过表达获得的生长优势,表明Erg是Trib1/Hoxa9轴的关键下游靶点。
  • BRD4抑制剂JQ1在体外和体内以Trib1/Erg依赖方式抑制急性髓系白血病细胞生长。
  • 人急性髓系白血病细胞系中观察到TRIB1上调ERG。

临床怎么用

  • 原文结论提示Trib1是Hoxa9相关急性髓系白血病的潜在治疗靶点,未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The pseudokinase Trib1 functions as a myeloid oncogene that recruits the E3 ubiquitin ligase COP1 to C/EBPα and interacts with MEK1 to enhance extracellular signal-regulated kinase (ERK) phosphorylation. A close genetic effect of Trib1 on Hoxa9 has been observed in myeloid leukemogenesis, where Trib1 overexpression significantly accelerates Hoxa9-induced leukemia onset. However, the mechanism underlying how Trib1 functionally modulates Hoxa9 transcription activity is unclear. Herein, we provide evidence that Trib1 modulates Hoxa9-associated super-enhancers. Chromatin immunoprecipitation sequencing analysis identified increased histone H3K27Ac signals at super-enhancers of the Erg, Spns2, Rgl1, and Pik3cd loci, as well as increased messenger RNA expression of these genes. Modification of super-enhancer activity was mostly achieved via the degradation of C/EBPα p42 by Trib1, with a slight contribution from the MEK/ERK pathway. Silencing of Erg abrogated the growth advantage acquired by Trib1 overexpression, indicating that Erg is a critical downstream target of the Trib1/Hoxa9 axis. Moreover, treatment of acute myeloid leukemia (AML) cells with the BRD4 inhibitor JQ1 showed growth inhibition in a Trib1/Erg-dependent manner both in vitro and in vivo. Upregulation of ERG by TRIB1 was also observed in human AML cell lines, suggesting that Trib1 is a potential therapeutic target of Hoxa9-associated AML. Taken together, our study demonstrates a novel mechanism by which Trib1 modulates chromatin and Hoxa9-driven transcription in myeloid leukemogenesis.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Yoshino S, Yokoyama T, Sunami Y, et al. Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9. Blood. 2021. PMID: 32730594. doi:10.1182/blood.2019004586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。